Management of Grade 1-2 Infusion Reactions
For grade 1-2 infusion reactions, immediately stop or slow the infusion rate, provide symptomatic treatment, and once the patient is stable, restart the infusion at half the previous rate and titrate to tolerance. 1
Immediate Management Steps
When a grade 1-2 infusion reaction occurs, follow this algorithmic approach:
1. Stop or Slow the Infusion
- Interrupt the infusion immediately upon recognition of symptoms
- Do not continue at the current rate
- This is the universal first step across all anticancer therapies 1
2. Provide Symptomatic Treatment
The specific interventions depend on the presenting symptoms:
- For chills/rigors: Administer meperidine or other antipyretics
- For fever: Give antipyretics (paracetamol/acetaminophen)
- For mild dyspnea: Provide supplemental oxygen if needed
- For nausea: Administer antiemetics
- For mild hypotension: Give IV fluids (normal saline)
- For flushing/pruritus: Administer antihistamines (diphenhydramine 25-50 mg IV or oral equivalent)
3. Resume Infusion Protocol
Once symptoms resolve and the patient is stable:
- Restart at 50% of the previous infusion rate (half-rate restart is the standard across most agents) 1
- Titrate upward gradually as tolerated, monitoring continuously
- Close monitoring is essential during the remainder of the infusion
- Most patients can successfully complete the infusion with this approach 1
Drug-Specific Considerations
While the general approach is consistent, some agents have specific nuances:
- Rituximab and trastuzumab: Can typically resume after symptomatic treatment with close monitoring 1
- Daratumumab: Specifically requires resumption at half-rate with titration to tolerance 1
- Ipilimumab: Restart with particularly close monitoring given the immune-mediated mechanism 1
- Checkpoint inhibitors (nivolumab, pembrolizumab): Stop or slow rate with symptomatic treatment; these rarely require permanent discontinuation for grade 1-2 reactions 1
Critical Pitfalls to Avoid
Do not simply continue the infusion at the same rate when symptoms develop—this risks progression to grade 3-4 reactions that may require permanent discontinuation.
Do not automatically discontinue therapy for grade 1-2 reactions. The evidence consistently shows that >90% of patients can successfully complete infusions after appropriate management 1, 2, 3.
Do not assume all reactions are IgE-mediated anaphylaxis—most infusion reactions are not true type I hypersensitivity reactions, as demonstrated by normal tryptase levels during reactions 4. This is why antihistamines alone are often insufficient, and the infusion rate modification is the key intervention.
Timing and Monitoring
- Most grade 1-2 reactions occur during the first infusion, typically within the first 60 minutes 2, 3
- Peak incidence is within the first 2 hours of infusion 5
- Monitor vital signs every 15 minutes during the first hour, then every 30 minutes for the remainder of the infusion
- Reactions occurring after the first infusion are significantly less common (approximately 10% recurrence rate) 2
Subsequent Infusions
For patients who experienced a grade 1-2 reaction:
- Premedication for future doses may include enhanced prophylaxis with corticosteroids, antihistamines, and antipyretics 1
- Slower initial infusion rates for subsequent doses
- The vast majority of patients (85-90%) can continue therapy without recurrence 2, 3
The key principle is that grade 1-2 reactions are manageable and should not result in treatment discontinuation—they require intervention, rate adjustment, and close monitoring, but therapy can and should continue in nearly all cases.